© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Institutional Perspectives in Neurology: Multiple Sclerosis
Understanding Infection Risk With Multiple Sclerosis DMTs: Brian G. Weinshenker, MD
August 05, 2021
The professor of neurology at the Mayo Clinic College of Medicine discussed the need for evaluating infection risk of disease-modifying therapies amid a growing MS treatment landscape.
Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy
July 28, 2021
Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).
Ongoing Research in MS Differentiation: Oliver Tobin, MBBCh, BAO, PhD
July 21, 2021
The associate professor of neurology at Mayo Clinic Rochester discusses technological advancements and research efforts in relation to differential multiple sclerosis.
Biomarkers and MRI Use in Patients With MS: Oliver Tobin, MBBCh, BAO, PhD
July 21, 2021
The associate professor of neurology at Mayo Clinic Rochester, commented on biomarkers for identifying MS in patients, as well as the significance of new MS consensus guidelines.
Identifying Atypical Forms, Presentations of Demyelinating Disease: Oliver Tobin, MBBCh, BAO, PhD
July 20, 2021
The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.